Cancer biotech MacroGenics files for a $60 million IPO

By
A A A

MacroGenics, a clinical-stage biotech developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. The Rockville, MD-based company, which was founded in 2000 and booked $49 million in grant and collaboration revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol MGNX. MacroGenics initially filed confidentially on August 2, 2013. BofA Merrill Lynch and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Why Bankers Are Dishonest
Why Bankers Are Dishonest           

Stocks

Referenced

Most Active by Volume

54,237,138
  • $35.95 ▲ 4.66%
44,625,736
  • $40.235 ▼ 1.72%
42,772,848
  • $16.98 ▼ 0.47%
37,017,047
  • $9.69 ▲ 2.11%
35,364,080
  • $116.4275 ▲ 1.53%
33,322,239
  • $110.7234 ▲ 1.75%
26,265,637
  • $7.41 ▲ 2.14%
25,871,118
  • $8.98 ▲ 2.39%
As of 11/20/2014, 03:40 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com